Pulmonary arterial hypertension (PAH) is a serious cardiopulmonary disease characterized by progressive narrowing of the small pulmonary arteries and elevated pulmonary artery pressure, which can lead to right heart failure. Much has been learned about the rare familial form by the identification of predisposing genes, but the molecular basis of associated PAH (APAH) in the context of congenital heart defects or connective tissue disorder remains largely unknown. Even in familial PAH, the penetrance of these mutations is low and the additional genetic or environmental factors that contribute to the etiology of PAH are not well understood. Our approach focuses on understanding both the germline genetic variation that predisposes to PAH and also somatic changes arising within the lung that may contribute to the onset and/or progression of the disease. We have shown that in pulmonary artery endothelial cells (PAEC) isolated from explant lung tissue, one-third of PAH cases harbor large-scale chromosome abnormalities. This is a minimum estimate, since there are likely more subtle alterations that are below the resolution of the analyses we have performed thus far. Levels of DNA damage were markedly higher in PAH cells than controls, not only in PAEC but also in peripheral blood mononuclear cells (PBMC). The level of damage correlated strongly with the amount of reactive oxygen species (ROS). Patients' cells were also significantly more sensitive to DNA damaging chemotherapeutic agents than controls. Similar abnormalities were seen across heritable, idiopathic and associated PAH cases. Remarkably, we discovered that PBMC from relatives of patients show the same profile of increased ROS production, mutagen sensitivity and DNA damage, suggesting that it may be a genetically determined trait. Our central hypothesis is that PAH patients share an intrinsic susceptibility to DNA damage that pre-dates the onset of PAH, predisposing to genetic alterations that contribute to vascular remodeling following endothelial cell injury.
The aims of this study are to (1) determine the profile of DNA damage and repair in PAH cells, (2) identify the molecular basis of increased ROS and DNA damage, and (3) identify the genetic factors underlying increased DNA damage in PAH.

Public Health Relevance

Pulmonary arterial hypertension is a serious, potentially life-threatening disorder affecting the blood vessels of the lung and can lead to heart failure. It has a complex etiology and is not well understood. This study will examine the role of DNA damage in the pathogenesis of pulmonary hypertension. The long term aims are to better understand what causes pulmonary hypertension and who is most at risk, in order to improve diagnosis, refine therapeutic interventions and work towards prevention of the disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL098199-06
Application #
9271994
Study Section
Respiratory Integrative Biology and Translational Research Study Section (RIBT)
Program Officer
Xiao, Lei
Project Start
2009-12-01
Project End
2020-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
6
Fiscal Year
2017
Total Cost
$390,306
Indirect Cost
$144,056
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Gräf, Stefan; Haimel, Matthias; Bleda, Marta et al. (2018) Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun 9:1416
Drake, Kylie M; Federici, Chiara; Duong, Heng T et al. (2017) Genomic stability of pulmonary artery endothelial colony-forming cells in culture. Pulm Circ 7:421-427
Barnes, Jarrod W; Kucera, Elif T; Tian, Liping et al. (2016) Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol 55:564-575
Farha, Samar; Hu, Bo; Comhair, Suzy et al. (2016) Mitochondrial Haplogroups and Risk of Pulmonary Arterial Hypertension. PLoS One 11:e0156042
Machado, Rajiv D; Southgate, Laura; Eichstaedt, Christina A et al. (2015) Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Hum Mutat 36:1113-27
Drake, Kylie M; Comhair, Suzy A; Erzurum, Serpil C et al. (2015) Endothelial chromosome 13 deletion in congenital heart disease-associated pulmonary arterial hypertension dysregulates SMAD9 signaling. Am J Respir Crit Care Med 191:850-4
Long, Lu; Ormiston, Mark L; Yang, Xudong et al. (2015) Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 21:777-85
Spiekerkoetter, Edda; Sung, Yon K; Sudheendra, Deepti et al. (2015) Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 192:254-7
Federici, Chiara; Drake, Kylie M; Rigelsky, Christina M et al. (2015) Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 192:219-28
Drake, Kylie M; Dunmore, Benjamin J; McNelly, Lauren N et al. (2013) Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 49:403-9

Showing the most recent 10 out of 16 publications